Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Introduction Alzheimer’s disease (AD) is the most common form of dementia, and four medications are currently available as symptomatic therapies: three cholinesterase inhibitors (ChEI) and memantine. In June 2021, aducanumab was approved in the United States under an accelerated approval pathway as the first novel putative disease-modifying therapy (p-DMT) targeting the β-amyloid (Aβ) cascade in the brain. The combination of several monotherapies to address the multifactorial pathogenesis of neurodegenerative diseases is an anticipated next step.Areas covered The cholinergic hypothesis and the amyloid cascade hypothesis have been proposed as explanations for the pathogenesis of AD. Given the limited effectiveness of monotherapies based on these hypotheses, approaches using combination therapy are attempting to address the complexity of AD pathogenesis, including putative causative proteins-related neurodegeneration, neurotransmitters, and neuroinflammation, in a comprehensive manner.Expert opinion The efficacy of an initial or add-on combination approach to counteracting neurodegenerative processes and functional deterioration has been investigated. The combination of symptomatic therapies with approved anti-dementia medicines (one ChEI and memantine) has been found to be functionally effective for a moderately severe disease stage. Furthermore, combination strategies involving p-DMTs, symptomatic therapies, and neuro-regeneration may be useful in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cholinesterase inhibitors and memantine remain the standard treatments for mild, moderate to severe dementia, providing symptomatic relief and functional stabilization.”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [29]
In the citing paper
“Combined use with ChEIs, memantine shows slight cognitive and functional benefits in moderate to severe AD.29,30”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [29]
In the citing paper
“Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, helps regulate glutamate and is beneficial in moderate to severe AD, improving global functioning, cognition, and daily activities.28,29”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [29]
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“growth, and the development of rational combination therapies to treat the disease is necessary to resolve this problem [1,51].”
BackgroundRetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“One of the leading hypotheses, the ‘cholinergic hypothesis,’ originated from the finding that choline acetyltransferase levels are reduced in postmortem brain tissue in AD patients, suggesting a cholinergic deficiency that has been linked to clinical cognitive dysfunction [4].”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers
Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., & Wanker, E. E. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1437 · Cited by 1,434
Gamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328 · cited 1×
“phosphorylated tau (p-tau), neuroinflammatory gene expression, and microgliosis, while simultaneously maintaining neurogenesis [28,29].”
Backgroundvan der Steen, J. T., Radbruch, L., Hertogh, C. M., de Boer, M. E., Hughes, J. C., Larkin, P., Francke, A. L., Jünger, S., Gove, D., Firth, P., et al. (2014) · Palliative Medicine · doi:10.1177/0269216313493685 · Cited by 997
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Research works printed but not linked: 7
- Matsunaga S, 2014, Int J Neuropsychopharmacol, 18, 115
- Koola MM, 2018, J Geriatr Care Res, 5, 57
- Daruich A, 2019, Mol Vis, 25, 610
- Ismail R, 2018, Int J Alzheimers Dis, 2018, 6852303
- Russ TC, 2012, Cochrane Database Syst Rev, 2012, CD009132
- Ruthirakuhan MT, 2018, Cochrane Database Syst Rev, 5, CD012197
- Salloway S, 2021, JAMA Neurol, 79, e214161
Cited by
Tang, B., Wang, Y., & Ren, J. (2023) · Ibrain · doi:10.1002/ibra.12098 · Cited by 137
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 50
The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
Ahmad, N., Lesa, K. N., Sudarmanto, A., Fakhrudin, N., & Ikawati, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1070677 · Cited by 29
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 24
Metadata
- Authors
- Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M.
- Affiliations
- Jikei University School of Medicine (JP)
- Keio University (JP)
- Corresponding author
- Mimura, Masaru
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2022-03-01
- Volume
- 23
- Issue
- 6
- Pages
- 727-737
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4214559958
- Cited by
- 11
- References
- 62
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 5
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- not funded
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, cholinesterase inhibitors, memantine, aducanumab, disease-modifying therapy, amyloid hypothesis, cholinergic hypothesis, neuroinflammation, neurodegeneration, adjunctive therapy, nerve regeneration
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Drug Therapy, Combination, Humans, Memantine, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14656566.2022.2042514
- The paper
- Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022). Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2022.2042514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.